Last reviewed · How we verify
DOXAPRAM HYDROCHLORIDE
DOXAPRAM HYDROCHLORIDE is a drug. It is currently FDA-approved (first approved 1965).
At a glance
| Generic name | DOXAPRAM HYDROCHLORIDE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1965 |
Approved indications
Common side effects
- Increased blood pressure
- Pyrexia
- Flushing
- Sweating
- Paresthesia
- Feeling of warmth
- Burning sensation
- Apprehension
- Headache
- Dizziness
- Hyperactivity
- Nausea
Serious adverse events
- Convulsions
- Ventricular tachycardia
- Ventricular fibrillation
- Laryngospasm
- Bronchospasm
- Hallucinations
- Disorientation
- Involuntary movements
- Phlebitis
- Hemolysis
Key clinical trials
- Doxapram Administration on Diaphragmatic Excursion in Mechanically Ventilated Patients With Chronic Obstructive Pulmonary Disease Undergoing Spontaneous Breathing Trial
- Study to Investigate the Safety, Tolerability and Pharmacokinetics of QEV-817 Oral Suspension (PHASE1)
- Doxapram Therapy in Preterm Infants (DOXA Trial) (PHASE3)
- Population PK/PD of Off Label Drugs in Premature Neonates
- The Effect of Doxapram Versus Theophylline on Diaphragmatic Function (NA)
- Staccato Alprazolam in Panic Attack (PHASE2)
- Dosing Chart for Calculating the First Dose of Doxapram in Premature Infants (PHASE4)
- The Effect and Mechanism of Respiratory Stimulant Doxapram on Facilitating Emergence (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DOXAPRAM HYDROCHLORIDE CI brief — competitive landscape report
- DOXAPRAM HYDROCHLORIDE updates RSS · CI watch RSS
Frequently asked questions about DOXAPRAM HYDROCHLORIDE
What is DOXAPRAM HYDROCHLORIDE?
DOXAPRAM HYDROCHLORIDE is a Small molecule drug.
When was DOXAPRAM HYDROCHLORIDE approved?
DOXAPRAM HYDROCHLORIDE was first approved on 1965.
What development phase is DOXAPRAM HYDROCHLORIDE in?
DOXAPRAM HYDROCHLORIDE is FDA-approved (marketed).
What are the side effects of DOXAPRAM HYDROCHLORIDE?
Common side effects of DOXAPRAM HYDROCHLORIDE include Increased blood pressure, Pyrexia, Flushing, Sweating, Paresthesia, Feeling of warmth. Serious adverse events: Convulsions, Ventricular tachycardia, Ventricular fibrillation, Laryngospasm.
Related
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing